Richard N. Formica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard N. Formica has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Darren E. Stewart
Department of Surgery, NYU Langone Health, New York, New York
4 shared publications - John S. Gill
Professor of Medicine, University of British Columbia, Vancouver, Canada
3 shared publications - Alexander Wiseman
Centura Transplant, Denver, Colorado
2 shared publications - Bohdan Pomahac
Department of Surgery, Division of Plastic Surgery, Yale School of Medicine, New Haven, CT, United States
2 shared publications - David C. Mulligan
Department of Surgery, Yale University School of Medicine, New Haven
2 shared publications - Jamil R. Azzi
Department of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications
Latest Publications
- 26 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (9) , 2125-2137
A Sliding Scale AdaptiVe Expedited rescue algorithm for deceased donor kidney transplantation
- 26 March 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (9) , 2125-2137
A Sliding Scale AdaptiVe Expedited rescue algorithm for deceased donor kidney transplantation
- 2 January 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (1) , 76-79
Placing Organ Allocation Out of Sequence in the Proper Context
- 2 January 2026
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 26 (1) , 76-79
Placing Organ Allocation Out of Sequence in the Proper Context
- 18 August 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 225-226
The kidneys’ effect on the survival of multi-organ transplant recipients
- 18 August 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 225-226
The kidneys’ effect on the survival of multi-organ transplant recipients
- 3 June 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (6) , e70175
Skin Elasticity: A Potential Surrogate Marker for Facial Allograft Skin Fibrosis—A Case Series
Introduction: Rejection represents a major and common complication in vascularized composite allotransplantation (VCA). Over time, recurrent acute or chronic rejection can lead to vascular and dermal fibrosis and potentially graft loss. To date, a non‐invasive monitoring tool to capture chronic graft changes among VCA recipients has not been established. This pilot study aims to assess the potential value of noninvasive skin elasticity measurements for surveillance of longitudinal fibrosis of facial allografts. Methods: Viscoelasticity was non‐invasively assessed via triplicate measurements of the transplanted facial skin on bilateral cheeks and native skin on bilateral upper arms in six face transplant recipients using the well‐established Cutometer Dual MPA 580. Data were statistically compared with recipient/donor age, post‐transplant years (PTYs), and cumulative rejection burden (CRB), smoking status, ethnicities, and immunosuppressive regimens. Results: A significant ( p < 0.05) negative linear relationship between CRB and the Cutometer parameters R2 (gross elasticity), R5 (net elasticity), and R7 (elasticity recovery) was found, which was not observed in control measurements of native skin of VCA recipients. Results were ranked into a three‐level severity scale. Comparison with PTYs further revealed a significant negative linear relationship with R2 and R5 values. No statistically significant correlation was detected across R values when evaluated against recipient/donor age, smoking status, ethnicity, or immunosuppressive regimens. Conclusions: Although diagnosis and monitoring of rejection‐associated degenerative skin changes currently still rely on biopsies, this exploratory study identifies skin elasticity as a promising surrogate marker for facial allograft fibrosis.
- 3 June 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (6) , e70175
Skin Elasticity: A Potential Surrogate Marker for Facial Allograft Skin Fibrosis—A Case Series
Introduction: Rejection represents a major and common complication in vascularized composite allotransplantation (VCA). Over time, recurrent acute or chronic rejection can lead to vascular and dermal fibrosis and potentially graft loss. To date, a non‐invasive monitoring tool to capture chronic graft changes among VCA recipients has not been established. This pilot study aims to assess the potential value of noninvasive skin elasticity measurements for surveillance of longitudinal fibrosis of facial allografts. Methods: Viscoelasticity was non‐invasively assessed via triplicate measurements of the transplanted facial skin on bilateral cheeks and native skin on bilateral upper arms in six face transplant recipients using the well‐established Cutometer Dual MPA 580. Data were statistically compared with recipient/donor age, post‐transplant years (PTYs), and cumulative rejection burden (CRB), smoking status, ethnicities, and immunosuppressive regimens. Results: A significant ( p < 0.05) negative linear relationship between CRB and the Cutometer parameters R2 (gross elasticity), R5 (net elasticity), and R7 (elasticity recovery) was found, which was not observed in control measurements of native skin of VCA recipients. Results were ranked into a three‐level severity scale. Comparison with PTYs further revealed a significant negative linear relationship with R2 and R5 values. No statistically significant correlation was detected across R values when evaluated against recipient/donor age, smoking status, ethnicity, or immunosuppressive regimens. Conclusions: Although diagnosis and monitoring of rejection‐associated degenerative skin changes currently still rely on biopsies, this exploratory study identifies skin elasticity as a promising surrogate marker for facial allograft fibrosis.
- Open Access
- 15 October 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (3) , 611-622
Ten-year follow-up after face transplantation—A single-center retrospective cohort study
- 15 October 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (3) , 611-622
Open AccessTen-year follow-up after face transplantation—A single-center retrospective cohort study
- Open Access
- 19 February 2024
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 29, e943498-1-e943498-13
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Background: LCPT (Envarsus XR (R)) is a common once-daily, extended-release oral tacrolimus formulation used in kidney transplantation. However, there are minimal evidence-based recommendations regarding optimal dosing and treatment in the de novo and conversion settings. Material/Methods: Using Delphi methodology, 12 kidney transplantation experts with LCPT experience reviewed available data to determine potential consensus topics. Key statements regarding LCPT use were generated and disseminated to the panel in an online Delphi survey. Statements were either accepted, revised, or rejected based on the level of consensus, perceived strength of evidence, and alignment with clinical practice. Consensus was defined a priori as 375% agreement. Results: Twenty-three statements were generated: 14 focused on de novo LCPT use and 9 on general administration or LCPT conversion use. After 2 rounds, consensus was achieved for 11/14 of the former and 7/9 of the latter statements. In a de novo setting, LCPT was recognized as a first -line option based on its safety and efficacy compared to immediate-release tacrolimus. In particular, African Americans and rapid metabolizer populations were identified as preferred for first -line LCPT therapy. In a conversion setting, full consensus was achieved for converting to LCPT to address neurological adverse effects related to immediate-release tacrolimus and for the time required (approximately 7 days) for steady-state LCPT trough levels to be reached. Conclusions: When randomized clinical trials do not replicate current utilization patterns, the Delphi process can successfully generate consensus statements by expert clinicians to inform clinical decision-making for the use of LCPT in kidney transplant recipients.
- 19 February 2024
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 29, e943498-1-e943498-13
Open AccessUse of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Background: LCPT (Envarsus XR (R)) is a common once-daily, extended-release oral tacrolimus formulation used in kidney transplantation. However, there are minimal evidence-based recommendations regarding optimal dosing and treatment in the de novo and conversion settings. Material/Methods: Using Delphi methodology, 12 kidney transplantation experts with LCPT experience reviewed available data to determine potential consensus topics. Key statements regarding LCPT use were generated and disseminated to the panel in an online Delphi survey. Statements were either accepted, revised, or rejected based on the level of consensus, perceived strength of evidence, and alignment with clinical practice. Consensus was defined a priori as 375% agreement. Results: Twenty-three statements were generated: 14 focused on de novo LCPT use and 9 on general administration or LCPT conversion use. After 2 rounds, consensus was achieved for 11/14 of the former and 7/9 of the latter statements. In a de novo setting, LCPT was recognized as a first -line option based on its safety and efficacy compared to immediate-release tacrolimus. In particular, African Americans and rapid metabolizer populations were identified as preferred for first -line LCPT therapy. In a conversion setting, full consensus was achieved for converting to LCPT to address neurological adverse effects related to immediate-release tacrolimus and for the time required (approximately 7 days) for steady-state LCPT trough levels to be reached. Conclusions: When randomized clinical trials do not replicate current utilization patterns, the Delphi process can successfully generate consensus statements by expert clinicians to inform clinical decision-making for the use of LCPT in kidney transplant recipients.
- 5 April 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (5) , 554-556
The National Organ Transplant Act Must Be Updated to Meet the Demands of Transplantation's Future
- 5 April 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (5) , 554-556
The National Organ Transplant Act Must Be Updated to Meet the Demands of Transplantation's Future
- Open Access
- 21 March 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (7) , 875-890
Stakeholders’ perspectives on transplant metrics: the 2022 Scientific Registry of Transplant Recipients’ consensus conference
- 21 March 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (7) , 875-890
Open AccessStakeholders’ perspectives on transplant metrics: the 2022 Scientific Registry of Transplant Recipients’ consensus conference
- 1 January 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (1) , 14-16
The Unintended Consequences of Changes to the Organ Allocation Policy
- 1 January 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (1) , 14-16
The Unintended Consequences of Changes to the Organ Allocation Policy